Skip to main content
Delfa

← All assets

Sodium oligomannate

9 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

9

Ongoing

4

Recruiting

2

Completed

2

Sites

348

Countries

10

Endpoints

48

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 48 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1
Phase 3
2
Phase 4
4
Not applicable
2

Trials by status

Recruiting
2
Active, not recruiting
2
Completed
2
Suspended
1
Unknown
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
16
Behavior / neuropsychiatric
8
Function / daily living
7
Safety / tolerability / PK
6
Other clinical outcomes
4
Other (unclassified)
3
Fluid / digital biomarkers
2
Neuroimaging
1
Caregiver / quality of life
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 28 of 48 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

10

ADCS-Activities of Daily Living (ADCS-ADL)Function

7

Neuropsychiatric Inventory (NPI)Behavior

6

Mini-Mental State Examination (MMSE)Cognition

3

Montreal Cognitive Assessment (MoCA)Cognition

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

9 of 9

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
GREEN MEMORYA Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

Sodium oligomannate

Alzheimer’s disease

mild-to-moderate ADPh 3Suspended171Dec 2025-
NCT05058040A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

Sodium oligomannate

Alzheimer’s disease

Age ≥18Ph 4Active, not recruiting63Jan 2025-
NCT05908695An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Sodium oligomannate

Alzheimer’s disease

mild-to-moderate ADPh 4Recruiting50Jun 2029-
NCT05181475Long-term Efficacy and Safety Study of GV-971

Sodium oligomannate

Alzheimer’s disease

mild-to-moderate ADPh 4Active, not recruiting40Jan 2025-
NCT01453569Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease

Sodium oligomannate

Alzheimer’s disease

Alzheimer's diseasePh 2Completed24Aug 20131results
NCT02293915An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease

Sodium oligomannate

Alzheimer’s disease

Alzheimer's diseasePh 3Completed16Jun 20181
NCT05545605Efficacy and Safety of Sodium Oligomannate in the Prevention of PSCI

Sodium oligomannate

Vascular cognitive impairment / dementia

MoCA ≤22Not applicableRecruiting2Dec 2025-
NCT05114499Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer's Disease

Donepezil, Sodium oligomannate

Alzheimer’s disease

mild-to-moderate ADNot applicableUnknown0Dec 2023-
NCT05430867Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease

Memantine, Sodium oligomannate

Alzheimer’s disease

MMSE ≤14Ph 4Unknown0Jul 2024-

Showing 1-9 of 9 trials